Form 4 for ALNY ALNYLAM PHARMACEUTICALS, INC.
Accepted 2025-03-25 00:00:00 ET · period of report 2025-03-21 · accession 0001735276-25-000041 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| D | 2025-03-25 | 2025-03-24 | ALNY | Garg Pushkal | CMO, EVP Dev, Med Affairs | M - OptEx | $42.22 | +5,445 | 25.7K | +27% | +$229.9K |
| DM | 2025-03-25 | 2025-03-21+ | ALNY | Garg Pushkal | CMO, EVP Dev, Med Affairs | S - Sale+OE | $293.36 | -9,766 | 20.2K | -33% | -$2.86M |
| D | 2025-03-25 | 2025-03-24 | ALNY | Garg Pushkal | CMO, EVP Dev, Med Affairs | M - OptEx | $0.00 | -5,445 | 0 | -100% | $0 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2025-03-24 | M | A | 5,445 | $42.22 | 25,666 | D | — | — | |
| 2 | Common | Common Stock | 2025-03-24 | S | D | 5,445 | $300.00 | 20,221 | D | — | — | |
| 3 | Common | Common Stock | 2025-03-21 | S | D | 4,321 | $285.00 | 20,221 | D | — | — | |
| 4 | Derivative | Stock Option (right to buy) | 2025-03-24 | M | D | 5,445 | $0.00 | 0 | D | $42.22 · — to 2026-12-20 | 5,445 Common Stock | (F4) This stock option was fully vested and exercisable as of December 20, 2020. |